After a two-year stint running the Food and Drug Administration, Scott Gottlieb has joined the board of directors at Pfizer, giving the world’s largest drug maker crucial insights into the inner workings of the Trump administration as it attempts to contain national angst over the rising cost of medicines
Quick Read
After a motorcycle accident that almost took off his foot, Johns Hopkins bioethicist Travis Rieder became dependent on the pain medication he had been prescribed. Though he managed to wean himself off the drugs, the experience prompted him to write “In Pain: A Bioethicist’s Personal Struggle with Opioids.”
Quick Read
In Pain: A Bioethicist’s Personal Struggle with OpioidsJune 25, 2019 |
Listen Now: The Inquiring Minds Podcast talks to bioethicist Travis Rieder about his new book In Pain: A Bioethicist’s Personal Struggle with Opioids
Quick Read
For Some Critical Drugs, Low Prices Lead to ScarcityJune 19, 2019 |
Shortages of “supportive care” drugs, for chemotherapy-induced nausea or to protect the kidneys, can delay cancer treatments, said Yoram Unguru, a pediatric oncologist & bioethicist at Sinai and the Johns Hopkins Berman Institute of Bioethics. When he gets the hospital’s list of shortages, “I scream, I shout, I shake my head”
Quick Read
Move Over, Martin ShkreliJune 13, 2019 |
This Pharma Exec Is Accused Of Fixing Prices On 107 Drugs
Quick Read
Federal prosecutors accused the company of illegally marketing its powerful fentanyl painkiller and of defrauding government health care programs
Quick Read
As someone who has lived with spinal muscular atrophy for all 30 years of my life, I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price: $2.125 million
Quick Read
Cancer drugs that speed onto the market based on encouraging preliminary studies often don’t show clear benefits when more careful follow-up trials are done, according to research published Tuesday
Quick Read
